24СʱÈÈÃŰæ¿éÅÅÐаñ    

²é¿´: 1509  |  »Ø¸´: 5
±¾Ìû²úÉú 1 ¸ö ·­ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴

polarmouse

Ìú³æ (³õÈëÎÄ̳)

[ÇóÖú] ÇóÁ½¶Î·­Ò룬·Ç³£½ô¼±£¬¸Ð¼¤ÌéÁã

In open-label, randomized, three-period, three-treatment crossover studies, 10 subjects received 10 mg A, 45 mg B or the combination, while20 subjects received 20 mg A, 1000 mg C or the combination. In an open-label, randomized, five-period, five-treatment, unbalanced crossover study, 12 subjects first received 20 mg A, 4 mg D or the combination, and afterward 100 mg sitagliptin or sitagliptin plus 20 mg A. Blood samples were taken over 72 h of each treatmentperiod. Lack of PK interaction was defined as the ratio of geometric means and 90% confidence interval (CI) for combination:monotherapy being within the range of 0.80¨C1.25 ¡£
   Co-administration of A withB, C or D had no effect on A maximum plasma concentration (Cmax) or area under the plasma concentration-time curve (AUC). Similarly, A did not affect the Cmax or AUC for the co-administered drug, except for slight extensions of the 90% CI for the ratio of geometric means for B AUC (upper limit 1.29) andC Cmax (lower limit 0.75). All monotherapies and combination therapies were well tolerated.
    A can be co-administered with B¡¢C¡¢Dwithout dose adjustment of either drug
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

polarmouse

Ìú³æ (³õÈëÎÄ̳)

×ÔÒÑ´òÏÂÆø
2Â¥2011-05-08 11:43:15
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

polarmouse

Ìú³æ (³õÈëÎÄ̳)

ÔÚÏßµÈ
3Â¥2011-05-08 11:43:29
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

polarmouse

Ìú³æ (³õÈëÎÄ̳)

ÉÕÖùÏãÏÈ
4Â¥2011-05-08 11:43:49
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

Mally89

Ìú¸Ëľ³æ (Ö°Òµ×÷¼Ò)

T_T

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
sltmac(½ð±Ò+41, ·­ÒëEPI+1): 2011-05-16 07:52:15
sltmac: ¼ÌÐøÅ¬Á¦~~ 2011-05-16 07:52:30
In open-label, randomized, three-period, three-treatment crossover studies, 10 subjects received 10 mg A, 45 mg B or the combination, while20 subjects received 20 mg A, 1000 mg C or the combination. In an open-label, randomized, five-period, five-treatment, unbalanced crossover study, 12 subjects first received 20 mg A, 4 mg D or the combination, and afterward 100 mg sitagliptin or sitagliptin plus 20 mg A¡£
ÔÚ½øÐгÖÐøÈý¸öÖÜÆÚ£¬Ëæ»ú¿ª·Å±ê¼ÇµÄÈý¸ö´¦Àí½»²æÖÎÁÆÑо¿µ±ÖУ¬10¸öÑù±¾ÖмÓÈë10mgµÄA£¬45mgµÄB»òÕß¶þÕߵĻìºÏÎÁíÍâ20¸öÑù±¾ÖмÓÈë20mgµÄA¡¢1000mgµÄC»òÕß¶þÕߵĻìºÏÎï¡£ÔÚÁíÒ»¸öËæ»ú¿ª·Å±ê¼Ç£¬Î¬³Ö5¸öÖÜÆÚµÄ5¸ö½»²æ²»Æ½ºâ´¦ÀíÑо¿µ±ÖУ¬Ê×ÏÈÏò12¸öÑù±¾ÖмÓÈë20mg A£¬4mg D»òÕß¶þÕß»ìºÏÎȻºóÔÙ¼ÓÈë100mgÎ÷ËûÁÐÍ¡»ò¼ÓÓÐ20mgAµÄÎ÷ËûÁÐÍ¡¡£
5Â¥2011-05-08 15:22:48
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

Mally89

Ìú¸Ëľ³æ (Ö°Òµ×÷¼Ò)

T_T

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

Blood samples were taken over 72 h of each treatment period. Lack of PK interaction was defined as the ratio of geometric means and 90% confidence interval (CI) for combination:monotherapy being within the range of 0.80¨C1.25 ¡£
ÿ¸ö´¦ÀíÖÜÆÚ72Сʱ֮ºó½«ÑªÒºÑù±¾È¡³ö¡£¸ù¾Ý¼¸ºÎ·½·¨ºÍ»ìºÏÎï90%ÖÃÐÅÇø¼ä£¨ÔÚ0.8-1.25·¶Î§Äڵĵ¥Ò»ÖÎÁÆ£©µÄ±ÈÖµÀ´Åж¨½»²æ·´Ó¦ÖÐÊÇ·ñȱ·¦PK¡£
6Â¥2011-05-08 16:09:08
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ polarmouse µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[»ù½ðÉêÇë] Èç¹û´Ë¿ÌÄãÕýÔÚΪ¹ú»ù¸Ðµ½½¹ÂÇ£¬²»·ÁÀ´ÌýÌýÕâÊס¶»ù½ðÖ®Íâ¡· +4 scalable 2026-08-24 4/200 2026-08-24 16:22 by truewz
[»ù½ðÉêÇë] ¹À¼ÆÊÇÖÜËÄ +4 archvillain 2026-08-18 4/200 2026-08-24 13:53 by zzuzxg
[»ù½ðÉêÇë] ÎÒÃæÉÏÍêµ°ÁË +8 ÇÒÌý»¢Ð¥ 2026-08-20 9/450 2026-08-24 13:52 by zzuzxg
[»ù½ðÉêÇë] 2026¹ú×ÔÈ»º¯ÆÀ·Ñµ½ÕË +17 ÑòÑü°å 2026-08-21 18/900 2026-08-24 12:03 by iaeyuan
[»ù½ðÉêÇë] ½¨Òé»ù½ð·¢²¼Ìáǰ¸ø³öÃ÷È·µÄʱ¼äµã +12 kulium 2026-08-21 15/750 2026-08-24 12:02 by iaeyuan
[»ù½ðÉêÇë] ·¶½øÖоÙÒ»ÎĵÄÖÐÐÄ˼Ïë +6 Ñ׻ƹóëÐ 2026-08-22 7/350 2026-08-24 11:58 by 6543yes
[»ù½ðÉêÇë] ÈÃÎÒÖÐÒ»¸öÃæÉϰɣ¡ +13 ´óƼ1987 2026-08-20 16/800 2026-08-24 10:23 by ̫ɵÁË
[»ù½ðÉêÇë] ¿ÆÑй¶ùÌ«ÄÑÁË +18 ÎÒ4´ó°×²Ë 2026-08-20 19/950 2026-08-24 09:47 by ¿­¶÷¹ãÊ¢´ß»¯·ÖÎ
[»ù½ðÉêÇë] ʲôʱºò¿ª½±£¿ +10 CrisMessi 2026-08-18 11/550 2026-08-24 06:50 by ¿ªÐĵÄСʨ×Ó
[½Ìʦ֮¼Ò] Ìø²ÛºóÔÚÑÐÏîÄ¿Ôõô°ì£¿ +5 ¼òµ¥»¯xn 2026-08-22 10/500 2026-08-23 12:38 by ¼òµ¥»¯xn
[»ù½ðÉêÇë] ½ñÌì·Å°ñÂ𣿠+15 ²¼²¼ºÍÒ»¶þ 2026-08-19 16/800 2026-08-23 09:55 by ÕÅ´ºÉú
[»ù½ðÉêÇë] ½ñÌì»ù½ð»á³ö½á¹ûÂð£¿20260819 +16 kkkl_v 2026-08-19 17/850 2026-08-22 16:12 by °¢²¼Abu
[»ù½ðÉêÇë] ʱ¼ä´Á½ñÌ죬20ºÅ±äÁË +5 archvillain 2026-08-20 5/250 2026-08-22 06:12 by hui_daxiao
[»ù½ðÉêÇë] ¿´À´½ñÌì²»»á·Å°ñÁË£¿ +8 chengyan1220 2026-08-21 11/550 2026-08-21 17:52 by dcqxinyang
[ÂÛÎÄͶ¸å] Ͷ¸å×Éѯ +5 wwm09 2026-08-17 7/350 2026-08-21 10:11 by ÆÚ¿¯ÂÛÎİïÊÖ
[»ù½ðÉêÇë] ½ñÌì·Å°ñûϷÁ衃 +9 yuleib84 2026-08-19 11/550 2026-08-21 10:06 by gltch
[»ù½ðÉêÇë] »ù½ð°¡»ù½ð +4 longfie172 2026-08-20 4/200 2026-08-21 08:58 by mark mao
[»ù½ðÉêÇë] ÖØÒªÏûÏ¢£¬ÖÐÎçϵͳÔÚά»¤ +11 yuleib84 2026-08-18 12/600 2026-08-20 11:09 by xskun
[»ù½ðÉêÇë] Ã÷Ìì·Å°ñ£¿ +5 Shxjjxjkx 2026-08-18 5/250 2026-08-18 18:14 by -´ó´ó´ó´ó´ó-
[»ù½ðÉêÇë] ½ñÌìά»¤ÏµÍ³Î¬»¤ ×£ËùÓÐÈË ¸ßÖÐ +8 gjjjzhong 2026-08-18 9/450 2026-08-18 13:01 by ¼ÒÓëÔ¶·½
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û